This is a demo store. No orders will be fulfilled.

利替尼(PF-06651600), TEC 家族激酶抑制剂

JAK3 选择性抑制剂
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
R414045-5mg
5mg 现货 Stock Image
R414045-10mg
10mg 现货 Stock Image
R414045-25mg
25mg 现货 Stock Image
R414045-50mg
50mg 现货 Stock Image
R414045-100mg
100mg 现货 Stock Image

基本描述

别名 1-[(2S,5R)-2-甲基-5-(7H-吡咯并[2,3-d]嘧啶-4-基氨基)-1-哌啶基] -2-丙烯-1-酮丙二酸酯
英文别名 DB14924 | RITLECITINIB [WHO-DD] | PF06651600;PF 06651600 | GTPL9559 | DS-13951 | HY-100754 | AC-35550 | PF 06651600 | CCG-267324 | 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one | BCP24778 | SCHEMBL16764638 |
规格或纯度 Moligand™, ≥98%
英文名称 Ritlecitinib (PF-06651600)
生化机理 Ritlecitinib(PF-06651600)是一种强效、不可逆的 JAK3 选择性抑制剂,IC50 为 33.1 nM,但对 JAK1、JAK2 和 TYK2 没有活性(IC50 > 10 000 nM)。
储存温度 -20°C储存
运输条件 超低温冰袋运输
作用类型 抑制剂
作用机制 TEC 家族激酶抑制剂
产品介绍


Information

Ritlecitinib (PF-06651600) is a potent and irreversibleJAK3-selectiveinhibitor with an IC50 of 33.1 nM but without activity (IC50 > 10 000 nM) against JAK1, JAK2, and TYK2.


Targets

JAK3 (Cell-free assay) 33.1 nM


In vitro

PF-06651600, a newly discovered potent JAK3-selective inhibitor, is highly efficacious at inhibiting γc cytokine signaling, which is dependent on both JAK1 and JAK3. it inhibits Th1 and Th17 cell differentiation and function. In total lymphocytes in human whole blood, PF-06651600 inhibits the phosphorylation of STAT5 elicited by IL-2, IL-4, IL-7, and IL-15 with IC50 values of 244, 340, 407, and 266 nM, respectively, and it inhibits the phosphorylation of STAT3 elicited by IL-21 with an IC50 of 355 nM.


In vivo

PF-06651600 reduces disease pathology in rat adjuvant-induced arthritis as well as in mouse experimental autoimmune encephalomyelitis models. PF-06651600 has suitable pharmacokinetics and pharmacodynamics properties for preclinical and clinical evaluations. Human pharmacokinetics of PF-06651600 are predicted to show approximate values of blood clearance of 5.6 mL/min/kg, a steady state volume of distribution of 1.3 L/kg, oral bioavailability of 90%, and a systemic half-life of 2 h.

纯度 ≥98%

产品属性

IC50 JAK3, IC50: 33.1 nM
ALogP 1.854
hba_count 3
HBD Count 2
Rotatable Bond 3

关联靶点(人)

ITK Tclin 酪氨酸蛋白激酶 ITK/TSK(Tyrosine-protein kinase ITK/TSK) (1 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
JAK3 Tclin 酪氨酸蛋白激酶JAK3(Tyrosine-protein kinase JAK3) (6 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
JAK1 Tclin 酪氨酸蛋白激酶JAK1(Tyrosine-protein kinase JAK1) (1 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)
EGFR Tclin Epidermal growth factor receptor erbB1 (33727 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
ERBB2 Tclin Receptor protein-tyrosine kinase erbB-2 (7851 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
JAK3 Tclin Tyrosine-protein kinase JAK3 (8349 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
ITK Tclin Tyrosine-protein kinase ITK/TSK (3699 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
JAK1 Tclin Tyrosine-protein kinase JAK1 (8569 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
JAK2 Tclin Tyrosine-protein kinase JAK2 (12915 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
BLK Tchem Tyrosine-protein kinase BLK (2498 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
TYK2 Tclin Tyrosine-protein kinase TYK2 (5029 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
ERBB4 Tclin Receptor protein-tyrosine kinase erbB-4 (2748 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
MAP2K7 Tchem Dual specificity mitogen-activated protein kinase kinase 7 (1145 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
BMX Tchem Tyrosine-protein kinase BMX (1995 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
U-937 (7138 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
PBMC (10003 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
BTK Tclin Tyrosine-protein kinase BTK (8973 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
TXK Tchem Tyrosine-protein kinase TXK (1590 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
Liver (3974 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID

关联靶点(其它种属)

Tec Tyrosine-protein kinase TEC (25 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
Canis familiaris (36305 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
Mus musculus (284745 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
Rattus norvegicus (775804 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
Rhesus monkey (3147 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
BaF3 (4657 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
rep Replicase polyprotein 1ab (378 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
Blood (6 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
MDCKII-LE (120 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID
SARS-CoV-2 (38078 活性数据)
活性类型 Relation Activity value Units Action Type 期刊 PubMed Id doi Assay Aladdin ID

作用机制

作用机制 Action Type target ID Target Name Target Type Target Organism Binding Site Name 参考文献

名称和识别符

PubChem SID 504772852
分子类型 小分子
IIUPAC Name 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
INCHI 1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1
InChi Key CBRJPFGIXUFMTM-WDEREUQCSA-N
Smiles C=CC(N1[C@@H](C)CC[C@@H](NC2=C3C(NC=C3)=NC=N2)C1)=O
Isomeric SMILES C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3
PubChem CID 118115473
分子量 285.34

化学和物理性质

溶解性 Solubility (25°C) In vitro DMSO: 57 mg/mL (199.76 mM); Ethanol: 46 mg/mL (161.21 mM); Water: Insoluble;
DMSO(mg / mL) Max Solubility 57
DMSO(mM) Max Solubility 199.7616878
分子量 285.340 g/mol
XLogP3 2.100
氢键供体数Hydrogen Bond Donor Count 2
氢键受体数Hydrogen Bond Acceptor Count 4
可旋转键计数Rotatable Bond Count 3
精确质量Exact Mass 285.159 Da
单同位素质量Monoisotopic Mass 285.159 Da
拓扑极表面积Topological Polar Surface Area 73.900 Ų
重原子数Heavy Atom Count 21
形式电荷Formal Charge 0
复杂度Complexity 402.000
同位素原子数Isotope Atom Count 0
定义的原子立体中心计数Defined Atom Stereocenter Count 2
未定义的原子立体中心计数Undefined Atom Stereocenter Count 0
定义的键立体中心计数Defined Bond Stereocenter Count 0
未定义的键立体中心计数Undefined Bond Stereocenter Count 0
所有立体化学键的总数The total count of all stereochemical bonds 0
共价键合单元计数Covalently-Bonded Unit Count 1

安全和危险性(GHS)

象形图 GHS08
信号词 警告
危险声明

H302: 吞食有害

H315: 引起皮肤刺激

H319: 引起严重眼睛刺激

H335: 可能引起呼吸道刺激

预防措施声明

P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。

P405: 密闭存放

P501: 将内容物/容器处理到。。。

P203: 使用前,获取、阅读并遵守所有安全说明。

P318: 如果暴露或担心,请就医。

质检证书(CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!

找到10个结果

批号(Lot Number) 证书类型 货号
K2302032 分析证书 R414045
I2216421 分析证书 R414045
D2428471 分析证书 R414045
D2428472 分析证书 R414045
D2428473 分析证书 R414045
D2428474 分析证书 R414045
D2428475 分析证书 R414045
D2428476 分析证书 R414045
I2216413 分析证书 R414045
I2216420 分析证书 R414045

引用文献

1. Thorarensen A, Dowty ME, Banker ME, Juba B, Jussif J, Lin T, Vincent F, Czerwinski RM, Casimiro-Garcia A, Unwalla R et al..  (2017)  Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans..  J Med Chem,  60  (5): (1971-1993).  [PMID:28139931]
2. Telliez JB, Dowty ME, Wang L, Jussif J, Lin T, Li L, Moy E, Balbo P, Li W, Zhao Y et al..  (2016)  Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition..  ACS Chem Biol,  11  (12): (3442-3451).  [PMID:27791347]
3. King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L et al..  (2021)  A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results..  J Am Acad Dermatol,  85  (2): (379-387).  [PMID:33757798]
4. Robinson MF, Damjanov N, Stamenkovic B, Radunovic G, Kivitz A, Cox L, Manukyan Z, Banfield C, Saunders M, Chandra D et al..  (2020)  Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate..  Arthritis Rheumatol,  72  (10): (1621-1631).  [PMID:32419304]

溶液计算器